Current Vascular Pharmacology
Title:Acknowledgement
Volume: 10 Issue: 6
Author(s):
Affiliation:
Export Options
About this article
Cite this article as:
, Acknowledgement, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520828
DOI https://dx.doi.org/10.2174/157016112803520828 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Science of Calcium Channel Blocker to Inhibit Hypertensive Vascular Injury
Current Hypertension Reviews Recent Patents on Exoskeletal Rehabilitation Robot for Upper Limb
Recent Patents on Mechanical Engineering Hypocalcemia Induced by Raloxifene
Current Drug Safety Obesity, Metabolic Syndrome, Diabetes and Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent on Biomarkers in Medical Research: A Focus on Neuropsychiatric Disorders
Recent Patents on Biomarkers Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Current Pharmaceutical Design Endothelin-1 and Human Platelets
Current Vascular Pharmacology Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews Novel Antiarrhythmic Compounds with Combined Class IB and Class III Mode of Action
Current Medicinal Chemistry The Measurement of the QT Interval
Current Cardiology Reviews A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Effects of Pulmonary Hypertension and Right Ventricular Function in Short and Long-Term Kidney Function
Current Cardiology Reviews Tissue Factor and Hypertension
Current Hypertension Reviews Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology Cardiovascular Changes in Menopause
Current Cardiology Reviews Comment on Patient Adherence to Novel Oral Anticoagulants (NOACs) for the Treatment of Atrial Fibrillation and Occurrence of Associated Bleeding Events: A Systematic Review and Meta-analysis
Current Vascular Pharmacology Immune Modulation as a Therapeutic Strategy for Atherosclerosis
Current Drug Therapy TNF-α Polymorphisms and Maternal Depression in a Mexican Mestizo Population
CNS & Neurological Disorders - Drug Targets Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets